Zhitong Finance App News, Hualan Biotech (002007.SZ) issued an announcement. On September 22, 2026, Hualan Ankang Biology Co., Ltd., the company's shareholding company, received the “Notice of Acceptance” issued by the State Drug Administration, and its application for marketing license for injectable trastuzumab was accepted. Injectable trastuzumab is a monoclonal antibody targeting HER2. The original product name Herceptin is a core first-line drug for the treatment of HER2-positive breast cancer and gastric cancer. It is widely used clinically and is in high market demand.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.